Thirdly, the ability of five IRPGs to predict prognosis and response to immunotherapy could not be assessed by current methods such as using PD-L1 immunohistochemistry, or Nanostring tumor inflammation signature for lack of data in STS (68). The gene discussed is CD274; the disease is telomere syndrome.